# First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for <i>HER2</i> -altered NSCLC: a retrospective real-world POLISH study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-immunotherapy-or-angiogenesis-inhibitor-plus-chemotherapy-for-i-her2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Guangjian Yang,Yaning Yang,Runze Liu,Weihua Li,Haiyan Xu,Xuezhi Hao,Junling Li,Puyuan Xing,Shuyang Zhang,Xin Ai,Fei Xu,Yan Wang |
| Citations | 40 |
| DOI | 10.1177/17588359221082339 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://journals.sagepub.com/doi/pdf/10.1177/17588359221082339 |
| OpenAlex ID | https://openalex.org/W4214818973 |
| PMID | 35251321 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Xuezhi Hao](https://scholariq.org/researchers/xuezhi-hao/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.